Yinan Li, Wenting Wang, Yaoyao Wang, Ce Zhou, Xin Zou, Yixuan Wang, Ning Wang
{"title":"Nicotine-induced PD-L1 expression in lung squamous cell carcinoma is mediated by the α7-nAChR/STAT3 signaling pathway.","authors":"Yinan Li, Wenting Wang, Yaoyao Wang, Ce Zhou, Xin Zou, Yixuan Wang, Ning Wang","doi":"10.21037/tcr-2024-2587","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Nicotine, the principal addictive component of tobacco smoke, promotes lung cancer cell proliferation via α7 nicotinic acetylcholine receptors (α7-nAChRs). Programmed death-ligand 1 (PD-L1) serves as a crucial predictive biomarker for immune checkpoint inhibitor (ICI) therapy in lung squamous cell carcinoma (LUSC). This study aimed to investigate the expression patterns of α7-nAChR and its encoding gene <i>CHRNA7</i> in LUSC tissues, and to evaluate their associations with PD-L1 expression.</p><p><strong>Methods: </strong><i>CHRNA7</i> expression, its correlation with clinicopathological features, and survival outcomes in LUSC were analyzed using The Cancer Genome Atlas (TCGA) database and Kaplan-Meier plotter. The expression levels of α7-nAChR and PD-L1 in LUSC tissues and cell lines were evaluated by immunohistochemistry and Western blot (WB). Following nicotine stimulation and small interfering RNA (siRNA) transfection, messenger RNA (mRNA) expression levels of <i>CHRNA7</i>, signal transducer and activator of transcription 3 (STAT3), and CD274 (PD-L1) were quantified using quantitative real-time polymerase chain reaction (qRT-PCR), while their protein levels were assessed by WB.</p><p><strong>Results: </strong><i>CHRNA7</i> expression was significantly elevated in LUSC tissues and cell lines compared to adjacent normal tissues and bronchial epithelial cell lines (P<0.05), and correlated with smoking status. Higher <i>CHRNA7</i> expression was associated with shorter overall survival. Nicotine stimulation (1.0 μM) significantly increased the mRNA expression levels of <i>CHRNA7</i>, STAT3, and CD274 in LUSC cell lines. Knockdown of siRNA-mediated <i>CHRNA7</i> in LUSC cell lines decreased STAT3 phosphorylation (pSTAT3) and PD-L1 protein levels, while attenuating nicotine-induced PD-L1 upregulation. STAT3 silencing had no significant effect on α7-nAChR protein expression but downregulated PD-L1 protein levels and attenuated nicotine-induced PD-L1 upregulation.</p><p><strong>Conclusions: </strong>α7-nAChR and its encoding gene <i>CHRNA7</i> are upregulated in LUSC tissue and are associated with smoking status. Patients with high expression of <i>CHRNA7</i> have a relatively worse prognosis. Nicotine may upregulate PD-L1 expression in LUSC through the α7-nAChR/STAT3 pathway.</p>","PeriodicalId":23216,"journal":{"name":"Translational cancer research","volume":"14 7","pages":"4293-4304"},"PeriodicalIF":1.7000,"publicationDate":"2025-07-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC12335717/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Translational cancer research","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.21037/tcr-2024-2587","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"2025/6/19 0:00:00","PubModel":"Epub","JCR":"Q4","JCRName":"ONCOLOGY","Score":null,"Total":0}
引用次数: 0
Abstract
Background: Nicotine, the principal addictive component of tobacco smoke, promotes lung cancer cell proliferation via α7 nicotinic acetylcholine receptors (α7-nAChRs). Programmed death-ligand 1 (PD-L1) serves as a crucial predictive biomarker for immune checkpoint inhibitor (ICI) therapy in lung squamous cell carcinoma (LUSC). This study aimed to investigate the expression patterns of α7-nAChR and its encoding gene CHRNA7 in LUSC tissues, and to evaluate their associations with PD-L1 expression.
Methods: CHRNA7 expression, its correlation with clinicopathological features, and survival outcomes in LUSC were analyzed using The Cancer Genome Atlas (TCGA) database and Kaplan-Meier plotter. The expression levels of α7-nAChR and PD-L1 in LUSC tissues and cell lines were evaluated by immunohistochemistry and Western blot (WB). Following nicotine stimulation and small interfering RNA (siRNA) transfection, messenger RNA (mRNA) expression levels of CHRNA7, signal transducer and activator of transcription 3 (STAT3), and CD274 (PD-L1) were quantified using quantitative real-time polymerase chain reaction (qRT-PCR), while their protein levels were assessed by WB.
Results: CHRNA7 expression was significantly elevated in LUSC tissues and cell lines compared to adjacent normal tissues and bronchial epithelial cell lines (P<0.05), and correlated with smoking status. Higher CHRNA7 expression was associated with shorter overall survival. Nicotine stimulation (1.0 μM) significantly increased the mRNA expression levels of CHRNA7, STAT3, and CD274 in LUSC cell lines. Knockdown of siRNA-mediated CHRNA7 in LUSC cell lines decreased STAT3 phosphorylation (pSTAT3) and PD-L1 protein levels, while attenuating nicotine-induced PD-L1 upregulation. STAT3 silencing had no significant effect on α7-nAChR protein expression but downregulated PD-L1 protein levels and attenuated nicotine-induced PD-L1 upregulation.
Conclusions: α7-nAChR and its encoding gene CHRNA7 are upregulated in LUSC tissue and are associated with smoking status. Patients with high expression of CHRNA7 have a relatively worse prognosis. Nicotine may upregulate PD-L1 expression in LUSC through the α7-nAChR/STAT3 pathway.
期刊介绍:
Translational Cancer Research (Transl Cancer Res TCR; Print ISSN: 2218-676X; Online ISSN 2219-6803; http://tcr.amegroups.com/) is an Open Access, peer-reviewed journal, indexed in Science Citation Index Expanded (SCIE). TCR publishes laboratory studies of novel therapeutic interventions as well as clinical trials which evaluate new treatment paradigms for cancer; results of novel research investigations which bridge the laboratory and clinical settings including risk assessment, cellular and molecular characterization, prevention, detection, diagnosis and treatment of human cancers with the overall goal of improving the clinical care of cancer patients. The focus of TCR is original, peer-reviewed, science-based research that successfully advances clinical medicine toward the goal of improving patients'' quality of life. The editors and an international advisory group of scientists and clinician-scientists as well as other experts will hold TCR articles to the high-quality standards. We accept Original Articles as well as Review Articles, Editorials and Brief Articles.